Hyperinsulinemia, hyperglucemia, and impaired hemostasis - The Framingham offspring study

被引:430
作者
Meigs, JB [1 ]
Mittleman, MA
Nathan, DM
Tofler, GH
Singer, DE
Murphy-Sheehy, PM
Lipinsky, I
D'Angostino, R
Wilson, PWF
机构
[1] Massachusetts Gen Hosp, Gen Internal Med Unit S50 9, Div Gen Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Inst Prevent & Cardiovasc Dis, Cardiovasc Div,Beth Israel Deaconess Med Ctr, Boston, MA USA
[5] Boston Univ, Dept Math, Stat & Consulting Unit, Boston, MA 02215 USA
[6] Boston Univ, Sch Med, Boston, MA 02118 USA
[7] Framingham Heart Dis Epidemiol Study, Framingham, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 02期
关键词
D O I
10.1001/jama.283.2.221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Increased risk for cardiovascular disease in persons with glucose intolerance (impaired glucose tolerance and type 2 diabetes mellitus) is not fully explained by concomitant elevations in traditional atherosclerosis risk factors. Hyperinsulinemia associated with glucose intolerance may increase risk directly, or its effect could be mediated through impaired hemostatic function. Objective To evaluate associations between fasting insulin levels and hemostatic factors in subjects with normal and impaired glucose homeostasis. Design Cross-sectional analysis conducted between January 1991 and June 1995. Setting The population-based Framingham Offspring Study. Subjects A total of 1331 men and 1631 women aged 26 to 82 years, without diagnosed diabetes or cardiovascular disease and classified as having normal glucose tolerance (80.2%) or glucose intolerance (impaired glucose tolerance and impaired fasting glucose combined, 15.2%; previously undiagnosed diabetes, 4.7%) using an oral glucose tolerance test. Main Outcome Measures Trends across quintiles of fasting insulin in levels of plasminogen activator inhibitor 1 (PAI-1) antigen, tissue-type plasminogen activator (tPA) antigen, von Willebrand factor (VWF) antigen, factor VII antigen, fibrinogen, and plasma viscosity. We stratified analyses by sex and glucose tolerance status and adjusted hemostatic factor levels for obesity, lipid levels, and traditional cardiovascular disease risk factors. Results Mean levels of all hemostatic factors (except for fibrinogen in men) increased across fasting insulin quintiles among subjects with normal glucose tolerance (P<.001 for trend). Levels of PAI-1 and tPA antigens, but not other hemostatic factors, were higher comparing subjects with glucose intolerance with those with normal glucose tolerance (P<.001). Among subjects with glucose intolerance, levels of PAI-1 and tPA antigen in men and women (P<.01 for trend) and VWF antigen in men (P<.05 for trend) increased significantly across insulin quintiles, but levels of factor VII antigen, fibrinogen, and plasma viscosity did not increase. Conclusions Elevated levels of fasting insulin are associated with impaired fibrinolysis and hypercoagulability in subjects with normal glucose tolerance. Hyperinsulinemia is associated primarily with impaired fibrinolysis in subjects with glucose intolerance. Excess risk for cardiovascular disease associated with hyperinsulinemia and glucose intolerance may be mediated in part by enhanced potential for acute thrombosis.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 78 条
  • [1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
    Abraira, C
    Colwell, J
    Nuttall, F
    Sawin, CT
    Henderson, W
    Comstock, JP
    Emanuele, NV
    Levin, SR
    Pacold, I
    Lee, HS
    Silbert, CK
    Cxypoliski, R
    Vasquez, M
    Kernan, D
    Niewoehner, C
    Backes, M
    Bradley, M
    Bradley, M
    Crow, R
    Rubino, F
    Bushnell, D
    Pfeifer, M
    Service, FJ
    Howard, B
    Chew, E
    Hoogwerf, B
    Seigel, D
    Clark, CM
    Olefsky, JM
    Porte, D
    Sussman, KE
    Johnson, N
    Christine, B
    Tir, K
    Sather, M
    Day, P
    Morgan, N
    Deykin, D
    Gold, J
    Huang, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188
  • [2] ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491
  • [3] Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease
    Alessi, MC
    Peiretti, F
    Morange, P
    Henry, M
    Nalbone, G
    JuhanVague, I
    [J]. DIABETES, 1997, 46 (05) : 860 - 867
  • [4] EXPLORATION OF SIMPLE INSULIN SENSITIVITY MEASURES DERIVED FROM FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE-TOLERANCE (FSIGT) TESTS - THE INSULIN-RESISTANCE ATHEROSCLEROSIS STUDY
    ANDERSON, RL
    HAMMAN, RF
    SAVAGE, PJ
    SAAD, MF
    LAWS, A
    KADES, WW
    SANDS, RE
    CEFALU, W
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (07) : 724 - 732
  • [6] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
  • [7] RELATIONSHIP BETWEEN PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY AND VLDL TRIGLYCERIDE CONCENTRATION, INSULIN LEVELS AND INSULIN SENSITIVITY - STUDIES IN RANDOMLY SELECTED NORMOTRIGLYCERIDAEMIC AND HYPERTRIGLYCERIDEMIC MEN
    ASPLUNDCARLSON, A
    HAMSTEN, A
    WIMAN, B
    CARLSON, LA
    [J]. DIABETOLOGIA, 1993, 36 (09) : 817 - 825
  • [8] Does hyperglycemia really cause coronary heart disease?
    BarrettConnor, E
    [J]. DIABETES CARE, 1997, 20 (10) : 1620 - 1623
  • [9] BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
  • [10] Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
    Calles-Escandon, J
    Mirza, SA
    Sobel, BE
    Schneider, DJ
    [J]. DIABETES, 1998, 47 (02) : 290 - 293